H. Öztürk Et Al. , "Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy," 14th Congress of the International Ocular Inflammation Society , Lozan, Switzerland, pp.1-2, 2017
Öztürk, H. Et Al. 2017. Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. 14th Congress of the International Ocular Inflammation Society , (Lozan, Switzerland), 1-2.
Öztürk, H., ORAY, M., & Tuğal-Tutkun, İ., (2017). Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy . 14th Congress of the International Ocular Inflammation Society (pp.1-2). Lozan, Switzerland
Öztürk, Hilal, Merih ORAY, And İlknur Tuğal-Tutkun. "Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy," 14th Congress of the International Ocular Inflammation Society, Lozan, Switzerland, 2017
Öztürk, Hilal Et Al. "Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy." 14th Congress of the International Ocular Inflammation Society , Lozan, Switzerland, pp.1-2, 2017
Öztürk, H. ORAY, M. And Tuğal-Tutkun, İ. (2017) . "Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy." 14th Congress of the International Ocular Inflammation Society , Lozan, Switzerland, pp.1-2.
@conferencepaper{conferencepaper, author={Hilal Öztürk Et Al. }, title={Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy}, congress name={14th Congress of the International Ocular Inflammation Society}, city={Lozan}, country={Switzerland}, year={2017}, pages={1-2} }